| Identification | Back Directory | [Name]
Sincalide ammonium (Cholecystokinin octapeptide ammonium) | [CAS]
70706-98-8 | [Synonyms]
SQ19844 ammonium
Sincalide ammonium
Cholecystokinin octapeptide ammonium
Sincalide ammonium (Cholecystokinin octapeptide ammonium) | [Molecular Formula]
C49H65N11O16S3 | [MOL File]
70706-98-8.mol | [Molecular Weight]
1160.3 |
| Hazard Information | Back Directory | [Uses]
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK[1][2][3]. | [in vivo]
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model[4]. | Animal Model: | MI rat model[4] | | Dosage: | 50 μg/kg | | Administration: | i.p.; 50 μg/kg/d; for 4 weeks | | Result: | Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas. |
| [References]
[1] Maher KA. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100. DOI:10.1097/00001610-199110000-00008
[2] Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212. DOI:10.2967/jnmt.119.226019
[3] Can Wang, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020 Jul;121(7):3560-3569. DOI:10.1002/jcb.29639
[4] Can Wang, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020 Aug;125:105793. DOI:10.1016/j.biocel.2020.105793 |
|
|